Home › SEC Filings › Current Report (8-K)
Current Report (8-K)
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| CRSP | 8-K | neutral | 3/10 | CRISPR Therapeutics announced the promotion of Andrew J. Silver from SVP, Finance to CFO, effective October 19, 2026, re | Oct 19, 2026 |
| RXRX | 8-K | mixed | 6/10 | Recursion Pharmaceuticals filed an 8-K announcing a $200M oversubscribed follow-on offering of 61.54M shares at $3.25/sh | Oct 15, 2026 |
| ILMN | 8-K | neutral | 3/10 | Illumina established a $1.0 billion unsecured commercial paper program on October 8, 2026, with three dealers and a nati | Oct 13, 2026 |
| EDIT | 8-K | bullish | 6/10 | Editas Medicine announced regulatory approval in Australia to initiate the Phase 1/2 Strive clinical trial of EDIT-401, | Oct 8, 2026 |
| NEO | 8-K | mixed | 5/10 | NeoGenomics announced a planned CEO succession: President/COO Warren Stone will become CEO effective Jan 4, 2027, while | Oct 5, 2026 |
| FATE | 8-K | bullish | 5/10 | Fate Therapeutics received a $15 million CLIN2 grant from the California Institute for Regenerative Medicine (CIRM) to s | Sep 28, 2026 |
| RXRX | 8-K | mixed | 5/10 | Recursion Pharmaceuticals amended its Master Agreement with Tempus AI, extending the term from five to six years and eli | Sep 21, 2026 |
| BNGO | 8-K | bullish | 6/10 | Bionano Genomics presented an investor deck at the H.C. Wainwright conference, highlighting Q2 2026 revenue of $8.2M (ab | Sep 14, 2026 |
| NTLA | 8-K | bullish | 7/10 | Intellia Therapeutics announced FDA acceptance of its Biologics License Application (BLA) for lonvoguran ziclumeran (lon | Sep 9, 2026 |
| ILMN | 8-K | neutral | 3/10 | Illumina completed a $300M public offering of 4.950% notes due 2029. Net proceeds, together with cash on hand, will be u | Aug 17, 2026 |
| FATE | 8-K | neutral | 5/10 | Fate Therapeutics reported Q2 2026 results with a net loss of $0.25 per share, slightly beating the consensus estimate o | Aug 13, 2026 |
| ILMN | 8-K | neutral | 3/10 | Illumina issued $300M of 4.950% notes due 2029 via an underwritten public offering. The net proceeds, together with cash | Aug 12, 2026 |
| BNGO | 8-K | mixed | 5/10 | Bionano Genomics reported Q2 2026 revenue of $8.2M, up 21% YoY and above its own guidance of $7.5-7.8M, driven by 31% co | Aug 10, 2026 |
| NTLA | 8-K | mixed | 6/10 | Intellia Therapeutics reported Q2 2026 results with a net loss of $106.6M (-$0.80 EPS, -2.6% miss vs consensus) and coll | Aug 6, 2026 |
| RXRX | 8-K | mixed | 6/10 | Recursion reported Q2 2026 revenue of $7.7M (well below $12.0M consensus) and a GAAP net loss of -$0.25/share (vs -$0.23 | Aug 5, 2026 |
| TWST | 8-K | bullish | 7/10 | Twist Bioscience reported fiscal Q3 2026 revenue of $118.4M, a 23% YoY increase and above the $114.5M consensus estimate | Aug 3, 2026 |
| NEO | 8-K | neutral | 4/10 | NeoGenomics finalized a civil settlement with the DOJ for $9.8M, resolving a legacy investigation into consulting servic | Jul 20, 2026 |
| NTLA | 8-K | bullish | 7/10 | Intellia reported additional positive Phase 3 HAELO results for lonvo-z (CRISPR gene editing candidate) in hereditary an | Jun 15, 2026 |
| BNGO | 8-K | bearish | 4/10 | Alka Chaubey, Ph.D., resigned as Chief Medical Officer of Bionano Genomics, effective July 5, 2026. The filing provides | Jun 5, 2026 |
| PACB | 8-K | neutral | 3/10 | Pacific Biosciences (PACB) filed an 8-K reporting that shareholders approved an amendment to the 2020 Equity Incentive P | Jun 4, 2026 |
| CRSP | 8-K | neutral | 3/10 | CRISPR Therapeutics held its 2026 Annual General Meeting on June 4, 2026, where shareholders approved routine items incl | Jun 4, 2026 |
| FATE | 8-K | neutral | 4/10 | Fate Therapeutics filed an 8-K on June 4, 2026, to update its corporate presentation for the EULAR 2026 Congress, highli | Jun 4, 2026 |
| BNGO | 8-K | bullish | 5/10 | Bionano Genomics fully retired its $20M Senior Secured Convertible Debentures using cash on hand, eliminating all secure | May 28, 2026 |
| EDIT | 8-K | bearish | 7/10 | Editas Medicine priced a dilutive underwritten public offering of 55,555,556 shares of common stock and accompanying war | May 26, 2026 |
| EDIT | 8-K | bullish | 5/10 | Editas Medicine suspended and terminated the prospectus supplement under its at-the-market (ATM) offering agreement with | May 26, 2026 |
| NEO | 8-K | neutral | 2/10 | NeoGenomics held its 2026 annual meeting on May 21, 2026, with 89.61% of outstanding shares represented. Stockholders ap | May 22, 2026 |
| EDIT | 8-K | bullish | 6/10 | Editas Medicine reported new preclinical data for EDIT-401, its lead in vivo gene editing candidate for hyperlipidemia, | May 14, 2026 |
| FATE | 8-K | neutral | 5/10 | Fate Therapeutics reported Q1 2026 results with a net loss of $0.26 per share, slightly narrower than the $0.32 loss in | May 13, 2026 |
| NTLA | 8-K | mixed | 6/10 | Intellia reported Q1 2026 results with a net loss of $96.2M ($-0.81/share), narrower than the $114.3M loss in Q1 2025, w | May 11, 2026 |
| EDIT | 8-K | neutral | 4/10 | Editas Medicine reported Q1 2026 results with a net loss of $0.26 per share, narrower than the $0.92 loss in Q1 2025, dr | May 5, 2026 |
Page 1 of 2 Next »